PharmaDrug Advances PD-001 for Clinical Trials
Company Announcements

PharmaDrug Advances PD-001 for Clinical Trials

Story Highlights

Pharmadrug (TSE:PHRX) has released an update.

PharmaDrug’s Sairiyo Therapeutics has successfully completed a stability study of its reformulated cepharanthine, PD-001, paving the way for its Phase 1 clinical trial as a potential treatment for viral infectious diseases. This development marks a significant step forward in leveraging cepharanthine’s improved oral bioavailability for more effective therapeutic applications. The completion of the study allows the company to proceed with manufacturing and clinical trial preparations in Australia.

For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskPharmaDrug Debenture Units Issuance Announcement
TipRanks Canadian Auto-Generated NewsdeskPharmaDrug Begins Clinical Trial for Infectious Disease Treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App